Lithium carbonate

Brand Pharmstandard

In stock 1181 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Sedalit is a normochemical agent (it normalizes the mental state without causing general inhibition). Sedalit also has antidepressant, sedative and anti-manic effects. The effect is due to lithium ions, which, as antagonists of sodium ions, displace them from the cells and thereby reduce the bioelectric activity of brain neurons. Accelerates the breakdown of biogenic amines (reduced concentration of norepinephrine and serotonin in brain tissue). Sedalit increases the sensitivity of neurons of the hippocampus and other areas of the brain to the action of dopamine. Interacts with lipids formed during the metabolism of inositol.

Pharmacokinetics
When ingestion is absorbed from the gastrointestinal tract. Cmax of the active substance in plasma is reached after approximately 9 hours. Does not bind to plasma proteins. Gets through a placental barrier, it is allocated with breast milk. Not metabolized.
Excreted by the kidneys - 95%, with feces - less than 1%, with perspiration - 4-5%.

Indications

Manic and hypomanic states of various genesis,
prevention and treatment of affective psychoses,
prevention and treatment of affective disorders in patients with chronic alcoholism.
Migraine, Meniere's syndrome, sexual disorders, drug addiction.

Composition

1 tablet, film coated, contains: active ingredient: lithium carbonate 300 mg

No customer reviews for the moment.

Write your review

Dosage and Administration

The dose is determined by the level of lithium concentration in the blood plasma. adminstered orally. For adults, the dose is 300-600 mg 3-4 times / day. Therapeutic concentration of lithium in plasma - 0.6-1 mmol / l.

For children under the age of 12 - 15-20 mg 2-3 times / day.

Maximum Daily Dose for adults when administered is 2.4 g.

Adverse reactions

From the side of the central nervous system and peripheral nervous system: muscular weakness, hand tremor, weakness, drowsiness, with prolonged use, articulation disorders, hyperreflexia are possible.

Since the cardiovascular system: heart rhythm disorders.

From the digestive system: dyspepsia.

From the side of the endocrine system: rarely, dysfunction of the thyroid gland.

Other: increased thirst, impaired blood formation, leukocytosis, weight gain.

Contraindications

Leukemia
severe surgery
pregnancy,
lactation.

Drug interactions

With simultaneous use with thiazide diuretics, indapamide, a rapid increase in the concentration of lithium in the blood plasma and the development of toxic effects is possible.
With simultaneous use with ACE inhibitors, it is possible to increase the concentration of lithium in the blood plasma and the development of toxic effects; with NSAIDs - may increase the toxic effects of lithium; with iodine preparations - an increase in the risk of thyroid dysfunction is possible; with xanthine derivatives - it is possible to increase the elimination of lithium in the urine, which can lead to a decrease in its effectiveness.
With simultaneous use with alprazolam may be a clinically significant increase in the concentration of lithium in the blood plasma; with acyclovir - described a case of increased toxic action of lithium; with baclofen - described cases of increased hyperkinetic symptoms in patients with Huntington's chorea.

With simultaneous use of lithium carbonate with verapamil drug interaction is unpredictable. With the simultaneous use of lithium carbonate with diltiazem, a case of psychosis has been described.
With simultaneous use with haloperidol may increase extrapyramidal symptoms; with carbamazepine, clonazepam - possible development of neurotoxicity.
With simultaneous use with methyldopa, the toxic effect of lithium may develop; with metronidazole - it is possible to increase the concentration of lithium in the blood plasma.
When used simultaneously with sodium chloride, sodium bicarbonate, high sodium intake enhances the elimination of lithium, which can lead to a decrease in its effectiveness.
With simultaneous use with norepinephrine, it is possible to reduce the vasoconstrictor action of norepinephrine; with phenytoin - described the development of symptoms of toxic effects of lithium; with fluoxetine - it is possible to increase the concentration of lithium in the blood plasma and the development of toxic effects; with furosemide, bumetanide described cases of increased toxic action of lithium.
With simultaneous use with chlorpromazine and other phenothiazines, it is possible to decrease the absorption of phenothiazines from the gastrointestinal tract and reduce their plasma concentration by 40%, increase the intracellular concentration of lithium and its rate of excretion with urine, increase the risk of extrapyramidal reactions, cerebral dysfunction elderly people).

Pregnancy and Lactation

Contraindicated for use in pregnancy and lactation (breastfeeding).

Special instructions

It is used with caution in cardiovascular diseases (including AV block, intraventricular block), central nervous system diseases (including epilepsy, parkinsonism, organic lesions, schizophrenia), severe dehydration, infectious diseases, urinary retention, renal insufficiency, as well as in diabetes mellitus, hyperparathyroidism, thyrotoxicosis, psoriasis, in debilitated patients, and in hyponatremia of any etiology.
Elderly patients and debilitated patients require correction dosing regimen.
Nausea and vomiting, as early signs of lithium toxicity, may be masked by the antiemetic effect of some phenothiazines.
During the first month of therapy, the concentration of lithium in the blood plasma should be monitored weekly. When a stable concentration is reached, the control is carried out monthly, then once every 2-3 months.
During the period of treatment to prevent the use of alcohol.
Dosage forms of prolonged action should not be used in children under the age of 12 years, do not alternate with other dosage forms.

Influence on ability to drive motor transport and control mechanisms
During the period of treatment, care should be taken when driving vehicles and engaging in other potentially hazardous activities that require increased attention and speed of psychomotor reactions.